Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation

British Journal of Haematology

Volumn 155, Issue 3, 2011, Pages 318-327

  Marks, David I ^a   Pagliuca, Antonio ^b   Kibbler, Christopher C ^c   Glasmacher, Axel ^d   Heussel, Claus Peter ^e   Kantecki, Michal ^f   Miller, Paul J S ^g   Ribaud, Patricia ^h   Schlamm, Haran T ^f   Solano, Carlos ⁱ   Cook, Gordon ^j  

^a UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f PFIZER INC   (United States)

^g PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^j LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

more..

Author keywords

Azoles; Invasive fungal disease; Mould infections; Stem cell transplant; Yeast infections

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION PREVENTION; LIVER FUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOULD; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC MYCOSIS; SYSTEMIC THERAPY; TREATMENT DURATION; VISUAL IMPAIRMENT; VOMITING; YEAST;

ADOLESCENT; ANTIFUNGAL AGENTS; CHILD; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ITRACONAZOLE; MALE; MYCOSES; PROSPECTIVE STUDIES; PYRIMIDINES; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 84860390037     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08838.x     Document Type: Article

References (33)

1. Andrews, E., Damle, B.D., Fang, A., Foster, G., Crownover, P., LaBadie, R. & Glue, P. (2008) Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. British Journal of Clinical Pharmacology, 65, 531-539.
2. Ascioglu, S., Rex, J., De Pauw, B., Bennett, J.E., Bille, J., Crokaert, F., Denning, D.W., Donnelly, J.P., Edwards, J.E., Erjavec, Z., Fiere, D., Lortholary, O., Maertens, J., Meis, J.F., Patterson, T.F., Ritter, J., Selleslag, D., Shah, P.M., Stevens, D.A. & Walsh, T.J.; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. Clinical Infectious Diseases, 34, 7-14.
3. Atkinson, M.J., Sinha, A., Hass, S.L., Colman, S.S., Kumar, R.N., Brod, M. & Rowland, C.R. (2004) Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health and Quality of Life Outcomes, 2, 12.
4. Atkinson, M.J., Kumar, R., Cappelleri, J.C. & Hass, S.L. (2005) Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health, 8(suppl 1), S9-S24.
5. Bow, E.J., Laverdière, M., Lussier, N., Rotstein, C., Cheang, M.S. & Ioannou, S. (2002) Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer, 94, 3230-3246.
6. Cecil, J.A. & Wenzel, R.P. (2009) Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections. Expert Review of Hematology, 2, 237-254.
7. Cordonnier, C., Rovira, M., Maertens, J., Olavarria, E., Faucher, C., Bilger, K., Pigneux, A., Cornely, O.A., Ullmann, A.J., Bofarull, R.M., de la Cámara, R., Weisser, M., Liakopoulou, E., Abecasis, M., Heussel, C.P., Pineau, M., Ljungman, P. & Einsele, H.; Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI) study group; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation. (2010) Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica, 95, 1762-1768.
8. Cornely, O.A., Maertens, J., Winston, D.J., Perfect, J., Ullmann, A.J., Walsh, T.J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.T., Petrini, M., Hardalo, C., Suresh, R. & Angulo-Gonzalez, D. (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. New England Journal of Medicine, 356, 348-359.
9. Fukuda, T., Boeckh, M., Carter, R.A., Sandmaier, B.M., Maris, M.B., Maloney, D.G., Martin, P.J., Storb, R.F. & Marr, K.A. (2003) Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood, 102, 827-833.
10. Garcia-Vidal, C., Upton, A., Kirby, K.A. & Marr, K.A. (2008) Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clinical Infectious Diseases, 47, 1041-1050.
11. Gergis, U., Markey, K., Greene, J., Kharfan-Dabaja, M., Field, T., Wetzstein, G., Schell, M.J., Huang, Y., Anasetti, C. & Perkins, J. (2010) Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplantation, 45, 662-667.
12. Glasmacher, A., Prentice, A., Gorschlüter, M., Engelhart, S., Hahn, C., Djulbegovic, B. & Schmidt-Wolf, I.G. (2003) Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3, 597 subjects. Journal of Clinical Oncology, 21, 4615-4626.
13. Goodman, J.L., Winston, D.J., Greenfield, R.A., Chandrasekar, P.H., Fox, B., Kaizer, H., Shadduck, R.K., Shea, T.C., Stiff, P. & Friedman, D.J. (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine, 326, 845-851.
14. Herbrecht, R., Denning, D.W., Patterson, T.F., Bennett, J.E., Greene, R.E., Oestmann, J.W., Kern, W.V., Marr, K.A., Ribaud, P., Lortholary, O., Sylvester, R., Rubin, R.H., Wingard, J.R., Stark, P., Durand, C., Caillot, D., Thiel, E., Chandrasekar, P.H., Hodges, M.R., Schlamm, H.T., Troke, P.F. & de Pauw, B.; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine, 347, 408-415.
15. Kojima, R., Kami, M., Nannya, Y., Kusumi, E., Sakai, M., Tanaka, Y., Kanda, Y., Mori, S., Chiba, S., Miyakoshi, S., Tajima, K., Hirai, H., Taniguchi, S., Sakamaki, H. & Takaue, Y. (2004) Incidence of invasive aspergillosis after allogeneic hematopoietic stem cell transplantation with a reduced-intensity regimen compared with transplantation with a conventional regimen. Biology of Blood and Marrow Transplantation, 10, 645-652.
16. Kullberg, B.J., Sobel, J.D., Ruhnke, M., Pappas, P.G., Viscoli, C., Rex, J.H., Cleary, J.D., Rubinstein, E., Church, L.W., Brown, J.M., Schlamm, H.T., Oborska, I.T., Hilton, F. & Hodges, M.R. (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet, 366, 1435-1442.
17. Lin, S.J., Schranz, J. & Teutsch, S.M. (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clinical Infectious Diseases, 32, 358-366.
18. Marr, K.A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, S.A., Nichols, W.G., Musher, B. & Corey, L. (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood, 103, 1527-1533.
19. Marr, K.A., Laverdiere, M., Gugel, A. & Leisenring, W. (2005) Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clinical Infectious Diseases, 40, 1762-1769.
20. Martino, R., Caballero, M.D., Canals, C., San Miguel, J., Sierra, J., Rovira, M., Solano, C., Bargay, J., Pérez-Simon, J., León, A., Sarrá, J., Brunet, S. & de la Cámara, R.; alloPBSCT and Infectious/nonifectious Complications Subcommittees of the Grupo Español de Transplante Hematopoyético (GETH). (2001) Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplantation, 28, 341-347.
21. Martino, R., Subirá, M., Rovira, M., Solano, C., Vázquez, L., Sanz, G.F., Urbano-Ispizua, A., Brunet, S. & De la Cámara, R.; alloPBSCT Infectious/Non-infectious Complications Subcommittees of the Grupo Español de Trasplante Hematopoyético (GETH). (2002) Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. British Journal of Haematology, 116, 475-482.
22. Mikulska, M., Raiola, A.M., Bruno, B., Furfaro, E., Van Lint, M.T., Bregante, S., Ibatici, A., Del Bono, V., Bacigalupo, A. & Viscoli, C. (2009) Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients. Bone Marrow Transplantation, 44, 361-370.
23. Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K. & Marr, K. (2009) Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clinical Infectious Diseases, 48, 265-273.
24. Ninin, E., Milpied, N., Moreau, P., André-Richet, B., Morineau, N., Mahé, B., Vigier, M., Imbert, B.M., Morin, O., Harousseau, J.L. & Richet, H. (2001) Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clinical Infectious Diseases, 33, 41-47.
25. Queiroz-Telles, F., Goldani, L.Z., Schlamm, H.T., Goodrich, J.M., Espinell-Ingroff, A. & Shakanai-Yasuda, M.A. (2007) An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clinical Infectious Diseases, 45, 1462-1469.
26. Simon, A., Besuden, M., Vezmar, S., Hasan, C., Lampe, D., Kreutzberg, S., Glasmacher, A., Bode, U. & Fleischhack, G. (2007) Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Supportive Care in Cancer, 15, 213-220.
27. Slavin, M.A., Osborne, B., Adams, R., Levenstein, M.J., Schoch, H.G., Feldman, A.R., Meyers, J.D. & Bowden, R.A. (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation-a prospective, randomized, double-blind study. Journal of Infectious Diseases, 171, 1545-1552.
28. Srivatsan, V., Dasgupta, A.K., Kale, P., Datla, R.R., Soni, D., Patel, M., Patel, R. & Mavadhiya, C. (2004) Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography. Journal of Chromatography A, 1031, 307-313.
29. Ullmann, A.J., Lipton, J.H., Vesole, D.H., Chandrasekar, P., Langston, A., Tarantolo, S.R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., Pedicone, L., Patino, H. & Durrant, S. (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. New England Journal of Medicine, 356, 335-347. [Erratum in: New England Journal of Medicine, 357, 428.].
30. Upton, A., Kirby, K.A., Carpenter, P., Boeckh, M. & Marr, K.A. (2007) Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clinical Infectious Diseases, 44, 531-540.
31. Vardakas, K.Z., Michalopoulos, A. & Falagas, M.E. (2005) Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. British Journal of Haematology, 131, 22-28. [Erratum in: British Journal of Haematology (2006) 132, 665.].
32. Wingard, J.R., Carter, S.L., Walsh, T.J., Kurtzberg, J., Small, T.N., Baden, L.R., Gersten, I.D., Mendizabal, A.M., Leather, H.L., Confer, D.L., Maziarz, R.T., Stadtmauer, E.A., Bolaños-Meade, J., Brown, J., Dipersio, J.F., Boeckh, M. & Marr, K.A.; Blood and Marrow Transplant Clinical Trials Network. (2010) Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood, 116, 5111-5118.
33. Winston, D.J., Maziarz, R.T., Chandrasekar, P.H., Lazarus, H.M., Goldman, M., Blumer, J.L., Leitz, G.J. & Territo, M.C. (2003) Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. Annals of Internal Medicine, 139, 705-714.